within Pharmacolibrary.Drugs.ATC.L;

model L04AG04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0028333333333333335,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0037,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Belimumab is a fully human monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS or BAFF) and is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE) in adults and pediatric patients. It is administered as an adjunct to standard therapy and reduces disease activity by limiting the survival and differentiation of B cells.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with SLE following intravenous administration. Mixed sex, adult patients, typical body weight 76 kg.</p><h4>References</h4><ol><li><p>Brunner, HI, et al., &amp; Ruperto, N (2020). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. <i>Annals of the rheumatic diseases</i> 79(10) 1340–1348. DOI:<a href=&quot;https://doi.org/10.1136/annrheumdis-2020-217101&quot;>10.1136/annrheumdis-2020-217101</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32699034/&quot;>https://pubmed.ncbi.nlm.nih.gov/32699034</a></p></li><li><p>Meng, X, et al., &amp; Lu, H (2021). Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study. <i>Rheumatology and therapy</i> 8(4) 1711–1724. DOI:<a href=&quot;https://doi.org/10.1007/s40744-021-00366-0&quot;>10.1007/s40744-021-00366-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34554352/&quot;>https://pubmed.ncbi.nlm.nih.gov/34554352</a></p></li><li><p>Dimelow, R, et al., &amp; Struemper, H (2021). Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. <i>Clinical pharmacology in drug development</i> 10(6) 622–633. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.889&quot;>10.1002/cpdd.889</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33245847/&quot;>https://pubmed.ncbi.nlm.nih.gov/33245847</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AG04;
